PALO ALTO, Calif., November 4, 2025 — Scilex Holding Company (Nasdaq: SCLX), a leading biopharmaceutical innovator specializing in non-opioid pain management, announced that it has secured an exclusive worldwide license from Datavault AI Inc. (Nasdaq: DVLT) to utilize its proprietary AI-driven data tokenization platform for genomic, DNA, diagnostic, and drug-development data. The agreement grants Scilex exclusive rights to develop and commercialize a Biotech Exchange Platform, an advanced digital ecosystem for securely tokenizing, trading, and monetizing biomedical data. This collaboration merges AI, blockchain, and bioinformatics, positioning Scilex as a trailblazer in the digital transformation of biopharma data assets.
Science Significance
The partnership represents a pioneering leap at the intersection of artificial intelligence and biomedical science. Datavault AI’s patented framework—supported by the pending U.S. patent application “Platform and Method for Tokenizing DNA Data”—enables secure cryptographic conversion of genetic and pharmaceutical data into traceable digital tokens. Using this system, Scilex aims to digitize real-world evidence, clinical-trial data, drug formulation metadata, and genomic insights into immutable, blockchain-secured units of information. These tokens can be accessed, exchanged, or licensed by authorized research entities in compliance with data privacy and consent regulations. This model could redefine biopharma knowledge management, allowing scientists to access validated datasets without jeopardizing proprietary or patient information. The combination of AI-driven analytics and secure data tokenization represents a major scientific step toward precision medicine, data democratization, and multi-institutional research collaboration.
Regulatory Significance
Tokenization of sensitive biomedical data demands rigorous compliance with global regulatory frameworks, and the Scilex–Datavault AI collaboration aligns with HIPAA, GDPR, and FDA data-integrity guidelines. The licensed platform integrates blockchain traceability, encryption, and consent management, ensuring full adherence to Good Clinical Practice (GCP) and Good Automated Manufacturing Practice (GAMP) standards. By embedding regulatory checkpoints into its architecture, the platform can verify data origin, modification history, and ownership transfers—all critical for regulatory submissions and clinical-trial reproducibility. The technology also supports FDA’s Real-World Evidence (RWE) and Digital Health Innovation Action Plan, facilitating the inclusion of tokenized datasets in regulatory review pipelines. Through this approach, Scilex establishes a regulatory-ready digital infrastructure that could set the benchmark for AI and blockchain adoption in life sciences.
Business Significance
Advertisement
The financial structure of this agreement underscores its scale and ambition. Scilex will make a non-refundable $10 million upfront payment, divided into four quarterly installments, followed by milestone-based payments up to $2.55 billion, contingent on commercial and revenue achievements. This long-term deal positions Scilex to capture value within the rapidly expanding $2 trillion global biotech data economy. Beyond financial implications, the initiative establishes Scilex as a data-driven pharmaceutical enterprise, leveraging tokenization to monetize intellectual property, clinical outcomes, and patient data under ethical frameworks. For Datavault AI, the collaboration opens a lucrative new sector—extending its AI technology from fintech and data analytics into healthcare and biotech. Together, the companies are building a scalable digital asset exchange for the life sciences, designed to attract biopharma innovators, academic researchers, investors, and regulators seeking transparent and compliant access to data-driven insights.
Patients’ Significance
For patients, particularly those contributing biological samples or participating in genomic and therapeutic studies, this partnership offers an unprecedented level of data ownership and transparency. By converting medical and genetic information into secure digital tokens, individuals can retain control over how their data is accessed, shared, or monetized—without sacrificing privacy. This model supports patient-centric innovation, where consent is embedded directly into the data architecture. Tokenized records could also enable personalized-treatment ecosystems, linking genomic data with targeted drug therapies while maintaining patient confidentiality. In the long term, this approach may empower patients to benefit financially or therapeutically from their data contributions, creating a more equitable model for research participation. For Scilex, this represents a commitment not only to technological advancement but also to ethical digital healthcare practices rooted in transparency and patient trust.
Policy Significance
This collaboration arrives at a pivotal moment as global policymakers accelerate the development of AI, blockchain, and digital-health governance frameworks. The U.S. Department of Health and Human Services and the European Commission are actively exploring how to standardize data-tokenization models for secure, cross-border research collaboration. Scilex’s initiative aligns with these objectives by implementing decentralized data validation, which supports policy goals for data sovereignty, privacy protection, and innovation incentives. Furthermore, the deal reinforces the Biden Administration’s National AI Strategy and EU Horizon Europe digital-health goals, both of which encourage responsible AI use and public–private partnerships in healthcare innovation. By integrating AI tokenization into biopharma, Scilex is helping to shape policy discourse around digital data ethics and patient rights, defining how biomedical data can serve both science and society.
The Scilex–Datavault AI partnership marks a transformative moment in the convergence of biotechnology and digital finance. By merging AI analytics, blockchain integrity, and pharma-grade compliance, Scilex is setting a precedent for how genomic, diagnostic, and therapeutic data can be securely commercialized in the 21st century. This initiative represents more than technological innovation—it symbolizes a shift toward data empowerment, transparency, and equitable monetization in healthcare. As the first biopharmaceutical company to operationalize data-tokenization at this scale, Scilex is redefining the boundaries of tech-enabled biopharma enterprise, paving the way for a new digital economy built on trust, security, and innovation.
Source: Scilex Holding Company press release
